{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T03:26:58Z","timestamp":1786505218676,"version":"build-2736575974"},"reference-count":109,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008840","name":"Imam Muhammad Ibn Saud Islamic University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008840","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.prp.2026.156607","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:22:45Z","timestamp":1782919365000},"page":"156607","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["CBF\u03b2\u2013SMMHC in inv(16) AML: Fusion biology, RUNX1 dysregulation, and therapeutic targeting of a leukemogenic protein\u2013protein interaction"],"prefix":"10.1016","volume":"286","author":[{"given":"Emadeldin M.","family":"Kamel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally Mostafa","family":"Khadrawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.M.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5080-0933","authenticated-orcid":false,"given":"Noha A.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleh","family":"Alkhedhairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faris F.","family":"Aba Alkhayl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al Mokhtar","family":"Lamsabhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.prp.2026.156607_bib1","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1182\/blood-2016-10-687830","article-title":"Role of RUNX1 in hematological malignancies","volume":"129","author":"Sood","year":"2017","journal-title":"Blood"},{"issue":"40","key":"10.1016\/j.prp.2026.156607_bib2","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.11357","article-title":"Targeting binding partners of the CBF\u03b2-SMMHC fusion protein for the treatment of inversion 16 acute myeloid leukemia","volume":"7","author":"Richter","year":"2016","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.prp.2026.156607_bib3","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/nsmb819","article-title":"CBF\u03b2 allosterically regulates the Runx1 Runt domain via a dynamic conformational equilibrium","volume":"11","author":"Yan","year":"2004","journal-title":"Nat. Struct. & Mol. Biol."},{"issue":"2","key":"10.1016\/j.prp.2026.156607_bib4","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1079-9796(03)00022-6","article-title":"Structural and functional characterization of Runx1, CBF\u03b2, and CBF\u03b2-SMMHC","volume":"30","author":"Zhang","year":"2003","journal-title":"Blood Cells Mol. Dis."},{"issue":"19","key":"10.1016\/j.prp.2026.156607_bib5","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood.2020009933","article-title":"Emerging therapies for inv(16) AML","volume":"137","author":"Surapally","year":"2021","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.prp.2026.156607_bib6","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1038\/sj.onc.1207748","article-title":"Mechanism of leukemogenesis by the inv(16) chimeric gene CBFB\/PEBP2B-MHY11","volume":"23","author":"Shigesada","year":"2004","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.prp.2026.156607_bib7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ccr.2005.12.014","article-title":"Cbf\u03b2-SMMHC induces distinct abnormal myeloid progenitors able to develop acute myeloid leukemia","volume":"9","author":"Kuo","year":"2006","journal-title":"Cancer Cell."},{"issue":"21","key":"10.1016\/j.prp.2026.156607_bib8","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1182\/blood.2020008802","article-title":"RUNX1 and inv(16) are frenemies in AML","volume":"136","author":"Rao","year":"2020","journal-title":"Blood"},{"issue":"6223","key":"10.1016\/j.prp.2026.156607_bib9","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1126\/science.aaa0314","article-title":"A small-molecule inhibitor of the aberrant transcription factor CBF\u03b2-SMMHC delays leukemia in mice","volume":"347","author":"Illendula","year":"2015","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.prp.2026.156607_bib10","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.cell.2018.05.048","article-title":"CBF\u03b2-SMMHC inhibition triggers apoptosis by disrupting MYC chromatin dynamics in acute myeloid leukemia","volume":"174","author":"Pulikkan","year":"2018","journal-title":"Cell"},{"issue":"47","key":"10.1016\/j.prp.2026.156607_bib11","doi-asserted-by":"crossref","first-page":"31534","DOI":"10.1074\/jbc.273.47.31534","article-title":"The Core Binding Factor (CBF) \u03b1 Interaction Domain and the Smooth Muscle Myosin Heavy Chain (SMMHC) Segment of CBF\u03b2-SMMHC Are Both Required to Slow Cell Proliferation *","volume":"273","author":"Cao","year":"1998","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.prp.2026.156607_bib12","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nsb831","article-title":"Altered affinity of CBF\u03b2-SMMHC for Runx1 explains its role in leukemogenesis","volume":"9","author":"Lukasik","year":"2002","journal-title":"Nat. Struct. Biol."},{"issue":"22","key":"10.1016\/j.prp.2026.156607_bib13","doi-asserted-by":"crossref","first-page":"12822","DOI":"10.1073\/pnas.96.22.12822","article-title":"The inv(16) encodes an acute myeloid leukemia 1 transcriptional corepressor","volume":"96","author":"Lutterbach","year":"1999","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"23","key":"10.1016\/j.prp.2026.156607_bib14","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1182\/blood.V126.23.3666.3666","article-title":"The Multimerization Domain of Cbf\u00df-SMMHC Is Required for Leukemogenesis","volume":"126","author":"Zhao","year":"2015","journal-title":"Blood"},{"issue":"40","key":"10.1016\/j.prp.2026.156607_bib15","doi-asserted-by":"crossref","first-page":"66255","DOI":"10.18632\/oncotarget.11357","article-title":"Targeting binding partners of the CBF\u03b2-SMMHC fusion protein for the treatment of inversion 16 acute myeloid leukemia","volume":"7","author":"Richter","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.prp.2026.156607_bib16","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1128\/MCB.23.2.607-619.2003","article-title":"The inv(16) Fusion Protein Associates with Corepressors via a Smooth Muscle Myosin Heavy-Chain Domain","volume":"23","author":"Durst","year":"2003","journal-title":"Mol. Cell. Biol."},{"issue":"10","key":"10.1016\/j.prp.2026.156607_bib17","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.chembiol.2007.09.006","article-title":"Allosteric Inhibition of the Protein-Protein Interaction between the Leukemia-Associated Proteins Runx1 and CBF\u03b2","volume":"14","author":"Gorczynski","year":"2007","journal-title":"Chem. & Biol."},{"key":"10.1016\/j.prp.2026.156607_bib18","series-title":"Structure and Biophysics of CBF\u03b2\/RUNX and Its Translocation Products, in RUNX Proteins in Development and Cancer","first-page":"21","author":"Tahirov","year":"2017"},{"issue":"5","key":"10.1016\/j.prp.2026.156607_bib19","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ccr.2010.03.022","article-title":"Accelerated Leukemogenesis by Truncated CBF\u03b2-SMMHC Defective in High-Affinity Binding with RUNX1","volume":"17","author":"Kamikubo","year":"2010","journal-title":"Cancer Cell."},{"issue":"4","key":"10.1016\/j.prp.2026.156607_bib20","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/sj.emboj.7601568","article-title":"Disease mutations in RUNX1 and RUNX2 create nonfunctional, dominant-negative, or hypomorphic alleles","volume":"26","author":"Matheny","year":"2007","journal-title":"Embo J."},{"issue":"21","key":"10.1016\/j.prp.2026.156607_bib21","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1182\/blood.2020007747","article-title":"RUNX1 and CBF\u03b2-SMMHC transactivate target genes together in abnormal myeloid progenitors for leukemia development","volume":"136","author":"Zhen","year":"2020","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.prp.2026.156607_bib22","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/86264","article-title":"The leukemia-associated AML1 (Runx1)\u2013CBF\u03b2 complex functions as a DNA-induced molecular clamp","volume":"8","author":"Bravo","year":"2001","journal-title":"Nat. Struct. Biol."},{"issue":"10","key":"10.1016\/j.prp.2026.156607_bib23","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/S0969-2126(02)00853-5","article-title":"DNA Recognition by the RUNX1 Transcription Factor Is Mediated by an Allosteric Transition in the RUNT Domain and by DNA Bending","volume":"10","author":"Bartfeld","year":"2002","journal-title":"Structure"},{"issue":"35","key":"10.1016\/j.prp.2026.156607_bib24","doi-asserted-by":"crossref","first-page":"33097","DOI":"10.1074\/jbc.M303972200","article-title":"Mutagenesis of the Runt Domain Defines Two Energetic Hot Spots for Heterodimerization with the Core Binding Factor \u03b2 Subunit *","volume":"278","author":"Zhang","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.prp.2026.156607_bib25","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0092-8674(01)00271-9","article-title":"Structural Analyses of DNA Recognition by the AML1\/Runx-1 Runt Domain and Its Allosteric Control by CBF \u03b2","volume":"104","author":"Tahirov","year":"2001","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.prp.2026.156607_bib26","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0022-2836(02)00702-7","article-title":"The RUNX1 Runt Domain at 1.25\u00c5 Resolution: A Structural Switch and Specifically Bound Chloride Ions Modulate DNA Binding","volume":"322","author":"B\u00e4ckstr\u00f6m","year":"2002","journal-title":"J. Mol. Biol."},{"issue":"50","key":"10.1016\/j.prp.2026.156607_bib27","doi-asserted-by":"crossref","first-page":"39579","DOI":"10.1074\/jbc.M007350200","article-title":"Energetic and Functional Contribution of Residues in the Core Binding Factor \u03b2 (CBF \u03b2) Subunit to Heterodimerization with CBF\u03b1 *","volume":"275","author":"Tang","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.prp.2026.156607_bib28","doi-asserted-by":"crossref","first-page":"7432","DOI":"10.1128\/MCB.18.12.7432","article-title":"The leukemic protein core binding factor beta (CBFbeta)-smooth-muscle myosin heavy chain sequesters CBFalpha2 into cytoskeletal filaments and aggregates","volume":"18","author":"Adya","year":"1998","journal-title":"Mol. Cell. Biol."},{"issue":"6","key":"10.1016\/j.prp.2026.156607_bib29","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/sj.onc.1201985","article-title":"The chimeric protein, PEBP2\u03b2\/CBF\u03b2-SMMHC, disorganizes cytoplasmic stress fibers and inhibits transcriptional activation","volume":"17","author":"Tanaka","year":"1998","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.prp.2026.156607_bib30","doi-asserted-by":"crossref","first-page":"7432","DOI":"10.1128\/MCB.18.12.7432","article-title":"The Leukemic Protein Core Binding Factor \u03b2 (CBF\u03b2)\u2013Smooth-Muscle Myosin Heavy Chain Sequesters CBF\u03b12 into Cytoskeletal Filaments and Aggregates","volume":"18","author":"Adya","year":"1998","journal-title":"Mol. Cell. Biol."},{"issue":"4","key":"10.1016\/j.prp.2026.156607_bib31","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0092-8674(00)81388-4","article-title":"Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knocked-in leukemia gene CBFB-MYH11","volume":"87","author":"Castilla","year":"1996","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.prp.2026.156607_bib32","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.stem.2015.08.004","article-title":"HDAC8 Inhibition Specifically Targets Inv(16) Acute Myeloid Leukemic Stem Cells by Restoring p53 Acetylation","volume":"17","author":"Qi","year":"2015","journal-title":"Cell. Stem Cell."},{"issue":"7","key":"10.1016\/j.prp.2026.156607_bib33","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1182\/blood-2009-06-227413","article-title":"Cbfb\/Runx1 repression\u2013independent blockage of differentiation and accumulation of Csf2rb-expressing cells by Cbfb-MYH11","volume":"115","author":"Hyde","year":"2010","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.prp.2026.156607_bib34","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1093\/emboj\/19.12.3004","article-title":"Structural basis for the heterodimeric interaction between the acute leukaemia-associated transcription factors AML1 and CBF\u03b2","volume":"19","author":"Warren","year":"2000","journal-title":"EMBO J."},{"issue":"7","key":"10.1016\/j.prp.2026.156607_bib35","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/10658","article-title":"Immunoglobulin motif DNA recognition and heterodimerization of the PEBP2\/CBF Runt domain","volume":"6","author":"Nagata","year":"1999","journal-title":"Nat. Struct. Biol."},{"issue":"2","key":"10.1016\/j.prp.2026.156607_bib36","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1006\/jmbi.2001.4596","article-title":"Functional mutagenesis of AML1\/RUNX1 and PEBP2\u03b2\/CBF\u03b2 define distinct, non-overlapping sites for DNA recognition and heterodimerization by the runt domain1 1Edited by M. Yaniv","volume":"308","author":"Nagata","year":"2001","journal-title":"J. Mol. Biol."},{"issue":"4","key":"10.1016\/j.prp.2026.156607_bib37","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrd1343","article-title":"Small-molecule inhibitors of protein\u2013protein interactions: progressing towards the dream","volume":"3","author":"Arkin","year":"2004","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"7172","key":"10.1016\/j.prp.2026.156607_bib38","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/nature06526","article-title":"Reaching for high-hanging fruit in drug discovery at protein\u2013protein interfaces","volume":"450","author":"Wells","year":"2007","journal-title":"Nature"},{"issue":"36","key":"10.1016\/j.prp.2026.156607_bib39","doi-asserted-by":"crossref","first-page":"14592","DOI":"10.1073\/pnas.1200037109","article-title":"Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1\u2013CBF\u03b2 interaction","volume":"109","author":"Cunningham","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"10","key":"10.1016\/j.prp.2026.156607_bib40","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.chembiol.2007.09.006","article-title":"Allosteric Inhibition of the Protein-Protein Interaction between the Leukemia-Associated Proteins Runx1 and CBF\u03b2","volume":"14","author":"Gorczynski","year":"2007","journal-title":"Chem. & Biol."},{"issue":"13","key":"10.1016\/j.prp.2026.156607_bib41","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1093\/nar\/gki724","article-title":"Cooperative binding of DNA and CBF\u03b2 to the Runt domain of the CBF\u03b1 studied via MD simulations","volume":"33","author":"Habtemariam","year":"2005","journal-title":"Nucleic Acids Res."},{"issue":"23","key":"10.1016\/j.prp.2026.156607_bib42","doi-asserted-by":"crossref","first-page":"8278","DOI":"10.1128\/MCB.22.23.8278-8291.2002","article-title":"Multimerization via Its Myosin Domain Facilitates Nuclear Localization and Inhibition of Core Binding Factor (CBF) Activities by the CBF\u03b2-Smooth Muscle Myosin Heavy Chain Myeloid Leukemia Oncoprotein","volume":"22","author":"Kummalue","year":"2002","journal-title":"Mol. Cell. Biol."},{"issue":"12","key":"10.1016\/j.prp.2026.156607_bib43","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1038\/leu.2017.262","article-title":"The C-terminal multimerization domain is essential for leukemia development by CBF\u03b2-SMMHC in a mouse knockin model","volume":"31","author":"Zhao","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.prp.2026.156607_bib44","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ebiom.2016.04.032","article-title":"Small Molecule Inhibitor of CBF\u03b2-RUNX Binding for RUNX Transcription Factor Driven Cancers","volume":"8","author":"Illendula","year":"2016","journal-title":"eBioMedicine"},{"issue":"2","key":"10.1016\/j.prp.2026.156607_bib45","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.ygyno.2018.03.005","article-title":"Small molecule inhibition of the CBF\u03b2\/RUNX interaction decreases ovarian cancer growth and migration through alterations in genes related to epithelial-to-mesenchymal transition","volume":"149","author":"Carlton","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"8","key":"10.1016\/j.prp.2026.156607_bib46","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1038\/s41375-019-0403-2","article-title":"RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation","volume":"33","author":"Zhou","year":"2019","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.prp.2026.156607_bib47","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1080\/10428194.2017.1410882","article-title":"A tool compound targeting the core binding factor Runt domain to disrupt binding to CBF\u03b2 in leukemic cells","volume":"59","author":"Oo","year":"2018","journal-title":"Leuk. & Lymphoma"},{"issue":"9","key":"10.1016\/j.prp.2026.156607_bib48","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1080\/10428194.2017.1410882","article-title":"A tool compound targeting the core binding factor Runt domain to disrupt binding to CBF\u03b2 in leukemic cells","volume":"59","author":"Oo","year":"2018","journal-title":"Leuk. Lymphoma"},{"issue":"5","key":"10.1016\/j.prp.2026.156607_bib49","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0092-8674(01)00271-9","article-title":"Structural analyses of DNA recognition by the AML1\/Runx-1 Runt domain and its allosteric control by CBF\u03b2","volume":"104","author":"Tahirov","year":"2001","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.prp.2026.156607_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23061479","article-title":"Targeting Transcription Factors for Cancer Treatment","volume":"23","author":"Lambert","year":"2018","journal-title":"Molecules"},{"issue":"23","key":"10.1016\/j.prp.2026.156607_bib51","doi-asserted-by":"crossref","first-page":"8278","DOI":"10.1128\/MCB.22.23.8278-8291.2002","article-title":"Multimerization via its myosin domain facilitates nuclear localization and inhibition of core binding factor (CBF) activities by the CBFbeta-smooth muscle myosin heavy chain myeloid leukemia oncoprotein","volume":"22","author":"Kummalue","year":"2002","journal-title":"Mol. Cell. Biol."},{"issue":"2","key":"10.1016\/j.prp.2026.156607_bib52","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1128\/MCB.23.2.607-619.2003","article-title":"The inv(16) fusion protein associates with corepressors via a smooth muscle myosin heavy-chain domain","volume":"23","author":"Durst","year":"2003","journal-title":"Mol. Cell. Biol."},{"issue":"1","key":"10.1016\/j.prp.2026.156607_bib53","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.cell.2018.05.048","article-title":"CBF\u03b2-SMMHC Inhibition Triggers Apoptosis by Disrupting MYC Chromatin Dynamics in Acute Myeloid Leukemia","volume":"174","author":"Pulikkan","year":"2018","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.prp.2026.156607_bib54","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.molcel.2011.11.032","article-title":"Direct Recruitment of Polycomb Repressive Complex 1 to Chromatin by Core Binding Transcription Factors","volume":"45","author":"Yu","year":"2012","journal-title":"Mol. Cell."},{"issue":"1","key":"10.1016\/j.prp.2026.156607_bib55","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.molcel.2013.10.030","article-title":"Polycomb-Dependent H3K27me1 and H3K27me2 Regulate Active Transcription and Enhancer Fidelity","volume":"53","author":"Ferrari","year":"2014","journal-title":"Mol. Cell."},{"issue":"24","key":"10.1016\/j.prp.2026.156607_bib56","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1101\/gad.232710.113","article-title":"Role of SWI\/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation","volume":"27","author":"Shi","year":"2013","journal-title":"Genes. Dev."},{"issue":"4","key":"10.1016\/j.prp.2026.156607_bib57","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2013.09.053","article-title":"Super-enhancers in the control of cell identity and disease","volume":"155","author":"Hnisz","year":"2013","journal-title":"Cell"},{"issue":"40","key":"10.1016\/j.prp.2026.156607_bib58","doi-asserted-by":"crossref","first-page":"16669","DOI":"10.1073\/pnas.1108190108","article-title":"Targeting MYC dependence in cancer by inhibiting BET bromodomains","volume":"108","author":"Mertz","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.prp.2026.156607_bib59","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1182\/blood-2005-12-012773","article-title":"Human CD34+ cells expressing the inv(16) fusion protein exhibit a myelomonocytic phenotype with greatly enhanced proliferative ability","volume":"108","author":"Wunderlich","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.prp.2026.156607_bib60","article-title":"Preleukemia and Leukemia-Initiating Cell Activity in inv(16) Acute Myeloid Leukemia","volume":"8 - 2018","author":"Pulikkan","year":"2018","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.prp.2026.156607_bib61","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"issue":"16","key":"10.1016\/j.prp.2026.156607_bib62","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1101\/gad.244368.114","article-title":"CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma","volume":"28","author":"Huang","year":"2014","journal-title":"Genes. Dev."},{"issue":"31","key":"10.1016\/j.prp.2026.156607_bib63","doi-asserted-by":"crossref","first-page":"10853","DOI":"10.1073\/pnas.0804821105","article-title":"mTORC1 promotes survival through translational control of Mcl-1","volume":"105","author":"Mills","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.prp.2026.156607_bib64","doi-asserted-by":"crossref","first-page":"5943","DOI":"10.2147\/OTT.S100515","article-title":"BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects","volume":"9","author":"Abedin","year":"2016","journal-title":"Onco Targets Ther."},{"issue":"11","key":"10.1016\/j.prp.2026.156607_bib65","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1158\/1078-0432.CCR-16-1903","article-title":"AMPK-ULK1-Mediated Autophagy Confers Resistance to BET Inhibitor JQ1 in Acute Myeloid Leukemia Stem Cells","volume":"23","author":"Jang","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.prp.2026.156607_bib66","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.prp.2026.156607_bib67","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.clml.2012.11.006","article-title":"Therapy of core binding factor acute myeloid leukemia: incremental improvements toward better long-term results","volume":"13","author":"Bhatt","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"6","key":"10.1016\/j.prp.2026.156607_bib68","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41408-021-00503-6","article-title":"Core binding factor acute myelogenous leukemia-2021 treatment algorithm","volume":"11","author":"Borthakur","year":"2021","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.prp.2026.156607_bib69","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.prp.2026.156607_bib70","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"New. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.prp.2026.156607_bib71","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib\/II Study","volume":"37","author":"Wei","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.prp.2026.156607_bib72","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.3892\/or.2013.2328","article-title":"Core binding factor acute myeloid leukaemia and c-KIT mutations","volume":"29","author":"Riera","year":"2013","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.prp.2026.156607_bib73","first-page":"20","article-title":"Detection of KIT mutations in core binding factor acute myeloid leukemia","volume":"10","author":"Badr","year":"2018","journal-title":"Leuk. Res. Rep."},{"issue":"15","key":"10.1016\/j.prp.2026.156607_bib74","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1182\/blood-2019-01-894980","article-title":"Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet","volume":"133","author":"Sanz","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.prp.2026.156607_bib75","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11020641","article-title":"Targeted Therapy Development in Acute Myeloid Leukemia","volume":"11","author":"Totiger","year":"2023","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.prp.2026.156607_bib76","doi-asserted-by":"crossref","first-page":"380","DOI":"10.20517\/cdr.2021.125","article-title":"Venetoclax resistance: mechanistic insights and future strategies","volume":"5","author":"Ong","year":"2022","journal-title":"Cancer Drug. Resist."},{"issue":"7","key":"10.1016\/j.prp.2026.156607_bib77","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/bloodadvances.2018029850","article-title":"Hematopoietic cytokines mediate resistance to targeted therapy in FLT3-ITD acute myeloid leukemia","volume":"3","author":"Sung","year":"2019","journal-title":"Blood Adv."},{"issue":"26","key":"10.1016\/j.prp.2026.156607_bib78","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.prp.2026.156607_bib79","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1182\/blood-2012-06-435669","article-title":"Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial","volume":"120","author":"Yin","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.prp.2026.156607_bib80","first-page":"481","article-title":"Detection of inv(16) and t(16;16) by fluorescence in situ hybridization in acute myeloid leukemia M4Eo","volume":"85","author":"Hernandez","year":"2000","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.prp.2026.156607_bib81","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2169\/internalmedicine.35.327","article-title":"CBFB\/MYH11 fusion transcripts in a case of acute myelogenous leukemia (M1) with partial deletion of the long arm of chromosome 16","volume":"35","author":"Usuki","year":"1996","journal-title":"Intern. Med."},{"issue":"5","key":"10.1016\/j.prp.2026.156607_bib82","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ccr.2010.03.022","article-title":"Accelerated leukemogenesis by truncated CBF beta-SMMHC defective in high-affinity binding with RUNX1","volume":"17","author":"Kamikubo","year":"2010","journal-title":"Cancer Cell."},{"issue":"2","key":"10.1016\/j.prp.2026.156607_bib83","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1182\/blood-2012-07-442772","article-title":"inv(16)\/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations","volume":"121","author":"Schwind","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.prp.2026.156607_bib84","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1182\/bloodadvances.2019000709","article-title":"Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11","volume":"4","author":"Ishikawa","year":"2020","journal-title":"Blood Adv."},{"issue":"15","key":"10.1016\/j.prp.2026.156607_bib85","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1182\/blood-2019-01-894980","article-title":"Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet","volume":"133","author":"Sanz","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.prp.2026.156607_bib86","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.clml.2023.01.002","volume":"23","author":"Shahzad","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"24","key":"10.1016\/j.prp.2026.156607_bib87","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.prp.2026.156607_bib88","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/leu.2015.141","article-title":"Somatic mutational landscape of AML with inv(16) or t(8;21) identifies patterns of clonal evolution in relapse leukemia","volume":"30","author":"Sood","year":"2016","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.prp.2026.156607_bib89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1532\/IJH97.05075","article-title":"Runx1\/AML1 in normal and abnormal hematopoiesis","volume":"82","author":"Yamagata","year":"2005","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.prp.2026.156607_bib90","series-title":"RUNX1 Familial Platelet Disorder with Associated Myeloid Malignancies","author":"Deuitch","year":"1993"},{"issue":"6223","key":"10.1016\/j.prp.2026.156607_bib91","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1126\/science.aaa0314","article-title":"Chemical biology. A small-molecule inhibitor of the aberrant transcription factor CBF\u03b2-SMMHC delays leukemia in mice","volume":"347","author":"Illendula","year":"2015","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.prp.2026.156607_bib92","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2011.048","article-title":"Differentiation syndrome in promyelocytic leukemia: clinical presentation, pathogenesis and treatment","volume":"3","author":"Rego","year":"2011","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"10.1016\/j.prp.2026.156607_bib93","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.3389\/fped.2019.00368","article-title":"Molecular Approaches to Treating Pediatric Leukemias","volume":"7","author":"Kuhlen","year":"2019","journal-title":"Front. Pediatr."},{"issue":"15","key":"10.1016\/j.prp.2026.156607_bib94","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.prp.2026.156607_bib95","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","article-title":"Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery","volume":"181","author":"Burslem","year":"2020","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.prp.2026.156607_bib96","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1074\/mcp.T300009-MCP200","article-title":"Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation","volume":"2","author":"Sakamoto","year":"2003","journal-title":"Mol. Cell. Proteom."},{"issue":"12","key":"10.1016\/j.prp.2026.156607_bib97","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1021\/ja039025z","article-title":"Chemical genetic control of protein levels: selective in vivo targeted degradation","volume":"126","author":"Schneekloth","year":"2004","journal-title":"J. Am. Chem. Soc."},{"issue":"3","key":"10.1016\/j.prp.2026.156607_bib98","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"1","key":"10.1016\/j.prp.2026.156607_bib99","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13045-020-00850-0","article-title":"The design and development of covalent protein-protein interaction inhibitors for cancer treatment","volume":"13","author":"Cheng","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2026.156607_bib100","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cell.2020.12.020","article-title":"The Rise of Molecular Glues","volume":"184","author":"Schreiber","year":"2021","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.prp.2026.156607_bib101","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1021\/ja0693587","article-title":"Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide","volume":"129","author":"Bernal","year":"2007","journal-title":"J. Am. Chem. Soc."},{"issue":"15","key":"10.1016\/j.prp.2026.156607_bib102","doi-asserted-by":"crossref","first-page":"6275","DOI":"10.1021\/jm4011675","article-title":"Hydrocarbon-stapled peptides: principles, practice, and progress","volume":"57","author":"Walensky","year":"2014","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.prp.2026.156607_bib103","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1042\/BCJ20160619","article-title":"Macrocycles as protein-protein interaction inhibitors","volume":"474","author":"Dougherty","year":"2017","journal-title":"Biochem. J."},{"issue":"10","key":"10.1016\/j.prp.2026.156607_bib104","doi-asserted-by":"crossref","first-page":"5127","DOI":"10.1172\/JCI137723","article-title":"CBFB-MYH11 fusion neoantigen enables T cell recognition and killing of acute myeloid leukemia","volume":"130","author":"Biernacki","year":"2020","journal-title":"J. Clin. Invest."},{"issue":"7327","key":"10.1016\/j.prp.2026.156607_bib105","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.prp.2026.156607_bib106","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.3324\/haematol.2016.161570","article-title":"Suppression of RUNX1\/ETO oncogenic activity by a small molecule inhibitor of tetramerization","volume":"102","author":"Julia","year":"2017","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.prp.2026.156607_bib107","article-title":"Interference with RUNX1\/ETO Leukemogenic Function by Cell-Penetrating Peptides Targeting the NHR2 Oligomerization Domain","volume":"2013","author":"Bartel","year":"2013","journal-title":"BioMed. Res. Int."},{"issue":"15","key":"10.1016\/j.prp.2026.156607_bib108","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: Chimeric molecules that target proteins to the Skp1\u2013Cullin\u2013F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"2","key":"10.1016\/j.prp.2026.156607_bib109","first-page":"145","article-title":"The Clinical, Molecular, and Mechanistic Basis of RUNX1 Mutations Identified in Hematological Malignancies","volume":"43","author":"Yokota","year":"2020","journal-title":"Mol. Cells"}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033826002608?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033826002608?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T02:27:07Z","timestamp":1786501627000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033826002608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":109,"alternative-id":["S0344033826002608"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2026.156607","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CBF\u03b2\u2013SMMHC in inv(16) AML: Fusion biology, RUNX1 dysregulation, and therapeutic targeting of a leukemogenic protein\u2013protein interaction","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2026.156607","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156607"}}